Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan: PREP inhibitor breakthroughs in COPD treatment bottlenecks, innovative drugs to help public health
Published Time：
2025-04-02
With the increasing number of COPD (Chronic Obstructive Pulmonary Disease) patients globally, existing treatments face the dual challenges of efficacy and compliance. COPD is one of the leading causes of respiratory failure and death worldwide, and while existing treatments have made progress, they still fail to effectively address issues such as acute exacerbations and prolonged disease progression. Health Yuan, through technological innovation, is developing a PREP inhibitor that will bring new hope to COPD patients while driving progress and development in the global COPD treatment field.
Developed in collaboration with Bayer, Health Yuan's PREP-targeted oral COPD medication inhibits prolyl endopeptidase (PREP) activity through a unique mechanism of action, effectively controlling inflammatory responses. This provides effective treatment while significantly reducing the risk of adverse reactions, offering patients a safer and more effective treatment option.
Precisely Targeting Market Needs: Technological Innovation Fills Treatment Gaps
Current COPD treatment primarily relies on bronchodilators and corticosteroids. While these medications have achieved some success in alleviating symptoms, they have limitations in controlling acute exacerbations and reducing recurrence rates. Furthermore, poor patient compliance and adverse reactions during treatment significantly reduce efficacy.
Health Yuan Pharmaceutical's Precise Insight Health Yuan Pharmaceutical has precisely identified the core needs of COPD patients and developed an oral PREP inhibitor. This drug, by targeting and inhibiting prolyl endopeptidase (PREP), reduces the production of COPD inflammatory mediators, significantly lowering the frequency of acute exacerbations and effectively slowing disease progression. This technological breakthrough is expected to not only fill a gap in COPD treatment but also provide patients with a convenient treatment option with clearer efficacy.
Technological Innovation and Patient Well-being: Oral Treatment Improves Compliance
The PREP inhibitor offers significant advantages over existing inhaled formulations. Compliance with inhaled medications has always been a challenge in COPD treatment, particularly among elderly and long-term patients. The oral administration of the PREP inhibitor allows for more convenient treatment, especially suitable for patients requiring long-term therapy.
Furthermore, during the development of the PREP inhibitor, Health Yuan focused on improving the drug's safety and tolerability. Through its unique mechanism of action in inhibiting prolyl endopeptidase (PREP) activity, it effectively controls inflammatory responses and significantly reduces the risk of adverse reactions.
From Innovation to Social Responsibility: The Social Mission of Health Yuan Pharmaceutical
Health Yuan's innovation is not limited to technological breakthroughs but also focuses on contributing to global public health. With the continued growth in the number of COPD patients worldwide, Health Yuan, by increasing its innovation efforts and collaborating with internationally renowned pharmaceutical companies, has developed a globally competitive oral PREP inhibitor, demonstrating its active role in addressing public health issues.
Furthermore, with supportive policies and expanding medical insurance coverage, the launch of the PREP inhibitor will accelerate the popularization of domestically produced drugs in the respiratory disease field and contribute to public health.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.